Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The presence or absence of human leukocyte antigen (HLA) antibodies, especially the strength of donor-specific HLA antibodies (DSAs), has important roles in clinical evaluation and diagnostic decision-making for solid-organ transplantation. Dilution patterns help to give a new sight of HLA epitopes. "Epitope matching" is likely to lower the risk of developing DSA and increase the likelihood of matching a compatible donor.
Methods: We collected data evaluating HLA antibodies with a titration study using mean fluorescence intensity.
Results: Diluting the serum of recipients can reduce potential inhibitory effects, accurately evaluate the intensity of donor-specific HLA antibodies, and guide surgeons to take or not take intervention measures. Dilution patterns also help to give a new sight of HLA epitopes.
Conclusion: We believe that from the viewpoint of HLA antibodies, the dilution model can provide new tools and insights for the study of HLA epitopes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891501 | PMC |
| http://dx.doi.org/10.1002/jcla.23632 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Role of Extracorporeal Photopheresis in Kidney Transplant Management.
Transplant Direct
September 2025
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Fundació de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
Extracorporeal photopheresis (ECP) is emerging as an apoptotic cell-based therapy that suppresses alloimmunity, promotes donor-specific regulation, and reduces the need for conventional maintenance immunosuppression. ECP therapy is associated with regulatory T-cell proliferation, anti-inflammatory effects, and reduction of anti-HLA antibodies, making ECP a possible alternative or adjunct treatment for preventing and treating transplant rejection. Presently, we have a limited understanding of the mechanisms of ECP action, and clinical evidence for efficacy in kidney transplantation is sparse.
View Article and Find Full Text PDFCell-targeted PD-1 agonists are potent NK-cell inhibitors.
Front Immunol
September 2025
Immunocore Ltd., Abingdon, United Kingdom.
Background: The programmed cell death protein 1 (PDCD1 or PD-1) is a key regulatory immune checkpoint and a major target for therapeutic intervention. In oncology, antibodies blocking the PD-1 pathway are used to activate immune cells to promote anti tumour immunity while in immune-mediated inflammatory diseases, PD-1 agonist molecules have the potential to achieve immune suppression. NK cells are a specialised population of innate lymphocytes able to recognize a large range of distressed cells including damaged tissues in autoimmune and inflammatory conditions.
View Article and Find Full Text PDFPre-transplant compatibility testing: Transition from CDCXM to flow cytometry in India.
Transpl Immunol
September 2025
Molecular and Transplant Immunology Laboratory, Department of Transfusion Medicine (Blood Center), Medanta-The Medicity, Gurgaon, Haryana, India.
Over 60 % of kidney transplant candidates are non-sensitised while remaining 40 % are sensitised because of previous exposure to human alloantigens during previous transplants, blood transfusions, and pregnancy in women. Pre-transplant compatibility testing is mandatory prior to renal transplantation for detecting the presence of donor-specific antibodies (DSAs), which are associated with early hyperacute/acute and later chronic rejections. Initially, complement-dependent cytotoxicity crossmatch (CDCXM) was used as a traditional method for detecting preformed DSAs.
View Article and Find Full Text PDFFirst use of imlifidase desensitization in a highly sensitized heart and liver transplant candidate: A case report.
Hum Immunol
September 2025
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.
View Article and Find Full Text PDFAssessing the adequacy of immunosuppression in pediatric liver transplantation with immune Monitoring: Are we there yet?
Hum Immunol
September 2025
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA. Electronic address:
Current approaches used for pediatric liver transplant (LT) surveillance have diagnostic limitations. We used pleximmune™ immune reactivity index (IRI) and anti-HLA donor specific antibody (DSA) to predict the adequacy of immunosuppression (IS) relative to risk of acute cellular rejection (ACR) at 1-year post LT. This is a retrospective chart review of children who underwent LT between January 1, 2016, through December 31, 2020, and had at least one pleximmune measurement performed within 60-days of a liver biopsy.
View Article and Find Full Text PDF